7 Best Peptides for Atherosclerosis

What to Know Before Choosing a Peptide for Atherosclerosis

Atherosclerosis is one of the more challenging goals in the peptide space, and that is worth saying plainly before diving into the list. The condition involves arterial plaque buildup driven by oxidized LDL, chronic inflammation, and macrophage infiltration, mechanisms that researchers are actively targeting with peptide candidates. But as of 2026, no peptide has cleared a Phase 3 clinical trial for atherosclerosis, and none are approved or standardly prescribed for it anywhere in the Western world. The research ranges from genuinely promising preclinical findings to early-phase human data to purely community-reported use with almost no formal science behind it.

A compound earns a slot here because people use it or are actively discussing using it for cardiovascular and arterial health, not because it has FDA approval or a deep bank of randomized controlled trials. FDA-approved compounds, telemedicine-prescribed compounds, and research-only compounds are all eligible under the same criterion. Where the evidence is strong, this guide says so. Where it amounts to animal studies only, or community-reported use with no clinical data, this guide says that too, compound by compound, clearly.

The entries are numbered by how prominently each appears in research and in real-world use for atherosclerosis, not as a ranking of one compound being better than another for you. The right compound for any individual depends on their specific situation, what their physician advises, and what they work through with a personalized plan.

1. BPC-157: The Most Specific Preclinical Data on Plaque

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. It is among the most studied peptides across tissue repair and cytoprotection broadly, and it sits at the top of this list because it is the only compound in the broader peptide-atherosclerosis field with data specifically on plaque stability, not just plaque size.

In studies using a standard atherosclerosis mouse model, BPC-157 reduced lesion area by roughly 38 percent compared to untreated controls. That figure alone is notable for an unapproved research compound, but the more significant finding is what happened to the plaques that remained. Collagen content inside the fibrous cap, the outer shell that keeps a plaque from rupturing, increased by around 14 to 18 percent. At the same time, levels of MMP-9, a matrix metalloproteinase that degrades the fibrous cap and is closely associated with plaque rupture risk, were suppressed. Think of MMP-9 as a chemical that slowly dissolves the protective wall around a plaque; BPC-157 appears to reduce that dissolving activity. Macrophage infiltration into the plaque was also reduced, along with vascular endothelial growth factor, which drives the formation of new blood vessels inside growing plaques and is linked to plaque vulnerability.

Put those pieces together and you get a compound that appears in animal models to be not just shrinking plaques but making the remaining plaques structurally more stable, with a tougher cap and less internal inflammatory activity. That is a different story from most compounds in this space, which focus primarily on lesion size alone.

The honest caveat is that all of this is preclinical. No human clinical trial has been published evaluating BPC-157 specifically for atherosclerosis as of 2026. The evidence is from rodent models, and the translation to human physiology has not been directly established. BPC-157 is available as a research compound, not as an approved therapeutic, and any use in humans falls outside regulatory approval. Physician supervision matters here.

2. ApoA-I Mimetic Peptides: The Most Clinically Advanced Class

ApoA-I mimetics are a family of synthetic peptides designed to mimic apolipoprotein A-I, the primary functional protein in HDL, the lipoprotein responsible for carrying cholesterol away from arterial walls and back to the liver. Where most atherosclerosis interventions try to lower LDL entering the arterial wall, ApoA-I mimetics work from the opposite direction, promoting reverse cholesterol transport, the process of pulling cholesterol out of foam cells already embedded in plaques.

The mechanism works like a cleanup crew dispatched directly to the problem site. The peptide binds to cholesterol-loaded macrophages inside the plaque, stabilizes the ABCA1 transporter on the macrophage surface, and triggers a signaling cascade that encourages the cell to offload its cholesterol to circulating particles, which carry it to the liver for clearance. At the same time, these peptides bind with high affinity to oxidized lipids, directly limiting LDL oxidation and reducing the inflammatory signaling that draws more immune cells into the plaque.

This class has actual human data behind it, which distinguishes it from nearly every other entry on this list. The compound AEM-28, an ApoE-based mimetic from this family, completed Phase 1a and Phase 2a trials in 51 patients via intravenous administration and produced more than a 50 percent reduction in triglycerides and VLDL-C compared to placebo, with safety confirmed in that trial. The peptide known as D-4F completed Phase 1 with anti-inflammatory blood levels achieved in humans. Peptide 5A is currently in active Phase 1 evaluation by the National Heart, Lung, and Blood Institute.

On the less encouraging side, ApoA-I Milano, perhaps the most prominent compound in this class historically, showed no significant plaque regression in human trials despite striking results in animal models. That gap between animal and human outcomes is a recurring theme across the entire atherosclerosis peptide field and is worth holding in mind when evaluating any preclinical finding.

Practical availability is the limiting factor for most people. These compounds are administered intravenously in clinical settings rather than self-administered as research chemicals. If you are looking at this class, you are looking at a clinical trial or supervised clinical pathway rather than a research-compound channel.

3. DT-109: The Strongest Translational Signal in the Preclinical Field

DT-109 is a tripeptide composed of glycine, glycine, and leucine. It would be easy to overlook on name recognition alone, but it has generated significant research interest because it is the only peptide in this space to show efficacy in nonhuman primates rather than just rodents, and that is a meaningful step toward human relevance.

In primate studies at the University of Michigan, DT-109 limited plaque formation in both the aorta and the coronary arteries. It also stopped vascular calcification, a component of advanced atherosclerosis that most other compounds in this space have not directly addressed. The mechanism centers on inhibiting the NLRP3 inflammasome, an intracellular protein complex that, when chronically activated, keeps the arterial environment in a state of persistent low-grade inflammation and drives calcium deposits into plaques. DT-109 appears to quiet that process.

A secondary finding adds to its profile. In the same primate models, DT-109 also showed effects on metabolic liver disease, which frequently co-occurs with advanced cardiovascular disease. That dual-target potential sets it apart from compounds with a narrower mechanism.

No human clinical trial has been published for DT-109 as of 2026. The primate data is the ceiling of what exists, and that is still several steps removed from a validated human therapy. The compound is not available outside research channels. What it represents is the strongest translational signal in the field: the closest any peptide has come to bridging the animal-to-human gap for atherosclerosis before a human trial.

4. Vesugen: The Vascular Bioregulator

Vesugen belongs to a class of short peptides developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The Khavinson peptides, sometimes called bioregulators, are designed as organ-specific interventions: each peptide in the series targets a particular tissue type and is theorized to influence gene expression there, acting as a localized regulatory signal. Vesugen's designated target is the vascular system.

The theoretical framework draws on epigenetic regulation research, specifically the idea that short peptides can interact with chromatin and modulate which genes are expressed in vascular cells. In that model, Vesugen is meant to support the structural and functional integrity of arterial walls rather than to directly reduce plaque burden in the way BPC-157 or the ApoA-I mimetics aim to. People working with Vesugen for cardiovascular support typically use it as part of broader Khavinson-based protocols, often combining it with Cardiogen and Ventfort.

The evidence situation is limited and worth stating plainly. No peer-reviewed clinical trial data specific to Vesugen's effects on atherosclerosis was available in the published literature as of 2026. The bulk of published Khavinson research comes from Russian institutions and addresses aging and tissue-specific bioregulation broadly rather than arterial plaque specifically. In the atherosclerosis context, what exists for Vesugen is community-reported use, primarily from practitioners and users familiar with the Khavinson tradition, without controlled human trial data to support specific cardiovascular outcomes. Vesugen is available as a research compound in Western markets.

5. Ventfort: Vascular Bioregulation Alongside Vesugen

Ventfort is Vesugen's closest sibling in the Khavinson series. Both compounds are classified as vascular bioregulators, both come from the same St. Petersburg research program, and both appear in the cardiovascular protocols used by people working within the Khavinson framework. The practical distinction between them is subtle and tends to reflect individual protocol design rather than a clear mechanistic difference between the two.

Like Vesugen, Ventfort is theorized to modulate gene expression in vascular tissue, acting as a tissue-specific epigenetic signal that nudges vascular cells toward healthier patterns of function. People who use Ventfort for arterial health typically combine it with Vesugen and Cardiogen, treating the three as complementary components of a vascular-support approach rather than as standalone interventions.

No clinical trial data specific to Ventfort's effects on arterial plaque or vascular inflammation was available in the published literature as of 2026. The research that exists covers the Khavinson bioregulator class broadly, and the atherosclerosis context for Ventfort reflects its consistent presence in community cardiovascular protocols rather than a formal clinical evidence trail. Its use for this goal is experiential rather than validated by controlled research. Ventfort is available as a research compound in Western markets, with a regulatory classification similar to Vesugen.

6. Cardiogen: Cardiac Tissue Support in the Context of Arterial Disease

Cardiogen rounds out the trio of Khavinson bioregulators most commonly discussed in cardiovascular protocols. Where Vesugen and Ventfort target vascular tissue, Cardiogen's designated target is the heart muscle itself. Its connection to atherosclerosis is indirect but coherent: atherosclerosis is the primary driver of coronary artery disease and cardiac events, and supporting cardiac tissue against the downstream consequences of arterial disease is part of how people approach this goal in practice.

The proposed mechanism follows the same Khavinson framework applied to a different tissue. Cardiogen is theorized to act as an epigenetic regulator in cardiac cells, supporting normal cellular function and tissue maintenance in heart muscle that may be under metabolic or inflammatory stress from reduced blood flow. In the atherosclerosis context, people using Cardiogen are generally thinking about preserving cardiac function while addressing arterial disease through parallel means, rather than expecting Cardiogen to directly reduce plaque.

As with the other Khavinson compounds on this list, the clinical evidence for Cardiogen in atherosclerosis is not established. No randomized controlled trial data specific to Cardiogen's effects on plaque, cardiac inflammation, or atherosclerosis-related endpoints was found in the published literature as of 2026. Its presence in cardiovascular protocols reflects the tradition of Khavinson peptide use rather than a published evidence base for this specific goal. Cardiogen is available as a research compound and is typically used alongside Vesugen and Ventfort by people working within that framework.

7. MOTS-c: A Mitochondria-Derived Peptide with Early Vascular Signals

MOTS-c is encoded not by the nuclear genome but by the mitochondrial genome, specifically within the 12S ribosomal RNA gene. That origin is unusual among the compounds on this list and gives MOTS-c a different biological story. Mitochondria-derived peptides act as cellular energy stress signals, communicating mitochondrial status to other systems in the body. MOTS-c has attracted growing attention for its effects on metabolic function and, more recently, on vascular biology.

In preclinical studies using an atherosclerosis mouse model on a high-fat diet, MOTS-c was associated with a lesion area reduction in the range of 22 to 28 percent and a reduction in macrophage infiltration into plaques of around 18 to 24 percent. Collagen content in the remaining plaques appeared to increase, a pattern that parallels the plaque-stabilizing signal observed with BPC-157, though the MOTS-c data is earlier-stage and less thoroughly characterized.

These findings are emerging and preliminary. The evidence comes from animal models only, and the mechanistic picture in the context of arterial disease is still being worked out. No human trial data exists for MOTS-c in atherosclerosis as of 2026. Research interest in this compound is growing because of its unusual origin and its connections to metabolic health and aging biology, but anyone working with it for cardiovascular goals is operating well ahead of the published science. MOTS-c is available as a research compound, and its use for atherosclerosis support is experimental.

How These Peptides Compare

Frequently Asked Questions

Are any peptides approved to treat atherosclerosis?

No peptide is currently FDA-approved or standardly prescribed for atherosclerosis anywhere in the Western world as of 2026. The most clinically advanced class, ApoA-I mimetics, has completed Phase 1 and Phase 2 trials showing safety and lipid-modifying effects in humans, but none have completed a Phase 3 trial or received regulatory approval. Every peptide on this list is either a research compound or in early-phase clinical investigation.

How does the evidence for these peptides compare to standard atherosclerosis treatments?

Standard care for atherosclerosis, including statins, PCSK9 inhibitors, and colchicine, is backed by large Phase 3 trials and long-term outcome data showing reductions in heart attacks and strokes. The peptides on this list are at a much earlier stage: most have animal data only, a few have early human safety and lipid data, and the Khavinson bioregulators are used primarily based on community protocols and a theoretical framework rather than controlled trials in atherosclerosis. That gap is real and worth understanding before exploring any of these compounds.

What makes plaque stabilization different from plaque size reduction?

Plaque size reduction refers to shrinking the overall volume of an arterial plaque, which is what most lipid-lowering therapies aim for. Plaque stabilization refers to making an existing plaque less likely to rupture, the event that actually triggers most heart attacks and strokes. A stable plaque has a thick fibrous cap, low macrophage content, and limited internal inflammation. BPC-157 stands out in this field because its animal data points toward both effects simultaneously, showing plaque size reduction alongside changes in plaque composition consistent with greater structural stability.

Is it safe to use research peptides for a serious cardiovascular condition?

The safety profiles for most peptides on this list have not been formally established in humans for cardiovascular use. Some, including ApoA-I mimetics like AEM-28, have confirmed safety in controlled Phase 1 and Phase 2 trials. Others, including the Khavinson bioregulators and BPC-157, lack formal cardiovascular safety trial data in humans. Anyone with an established cardiovascular condition should involve a qualified physician, use compounds from verifiable suppliers with transparent manufacturing standards, and hold realistic expectations about what the current evidence actually supports.

Why are there so few human trials for peptides in atherosclerosis?

Atherosclerosis research is expensive, requires long follow-up periods, and competes with well-established pharmaceutical options that already have regulatory approval. Most peptides in this space have not attracted the clinical trial investment needed to move from animal models to large human studies. The ApoA-I mimetic class is the notable exception, having received institutional funding including from the National Heart, Lung, and Blood Institute, which is why it is the only class with meaningful human trial data. For most other compounds, the research pipeline simply has not progressed to that stage yet.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and real-world use of peptides for atherosclerosis in one place.